This actually makes you want it, not just physically react. Felt the difference within a couple of hours. Much more natural than other options.
Lucien P. Verified Purchase
4.7 10 reviews

PT-141

The melanocortin peptide studied for sexual desire in women and men.

  • Works through the brain, not through blood flow
  • Increased desire in two phase 3 trials of 1,267 women
  • Also studied for erectile dysfunction in men
99.945% purity PASS Janoshik Analytical, Prague - Batch H6W2D9
View COA
Price range: £35,00 through £63,00
Bacteriostatic water 2ml vial FREE
1 free BAC water with every vial Worth £8 a bottle. Added automatically.
In Stock - Ships within 24h
How to use PT-141 Our own 17-step illustrated guide, from mixing to storage.
This actually makes you want it, not just physically react. Felt the difference within a couple of hours. Much more natural than other options.
Lucien P. Verified Purchase
Description

What Is PT-141?

PT-141 (Bremelanotide) is a synthetic peptide derived from Melanotan II that acts on melanocortin-4 receptors (MC4R) in the central nervous system. Unlike every other sexual dysfunction treatment on the market – PDE5 inhibitors (Viagra, Cialis) that work on blood vessel mechanics – PT-141 enhances sexual desire at the neurological level, addressing the psychological and neurochemical roots of low libido rather than just the physical symptoms.

This distinction is critical: PDE5 inhibitors can produce an erection but cannot create desire. PT-141 works upstream, activating the brain pathways responsible for sexual arousal, motivation, and desire. This makes it effective for both men and women – a rarity in sexual health pharmaceuticals. In fact, PT-141 (under the brand name Vyleesi) received FDA approval in 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.

How PT-141 Enhances Sexual Function

  • Central nervous system activation: PT-141 crosses the blood-brain barrier and binds to MC4R receptors in the hypothalamus – the brain region that governs sexual arousal, desire, and motivation. This triggers a neurochemical cascade that increases sexual interest and responsiveness.
  • Dopamine pathway involvement: PT-141’s mechanism involves the dopaminergic reward pathways associated with desire and motivation, producing a natural-feeling increase in sexual interest rather than an artificial or forced arousal.
  • Works for both sexes: Because it targets the brain’s desire centres rather than genital blood flow, PT-141 is effective for both men and women – one of the few compounds in sexual health that can make this claim.
  • Complementary to PDE5 inhibitors: For men, PT-141 can be used alongside Viagra or Cialis. PT-141 addresses desire and arousal at the brain level, while PDE5 inhibitors address the physical mechanics. The combination addresses sexual function comprehensively.
  • Extended duration: Effects typically begin 30–60 minutes after injection and can last 6–12 hours (sometimes up to 24 hours), providing a wide window of responsiveness rather than a timed “on/off” effect.

Clinical Evidence

PT-141 was evaluated in multiple clinical trials for both men and women. In men with erectile dysfunction, PT-141 produced erections in patients who had not responded to Viagra. In women with HSDD, clinical trials demonstrated statistically significant increases in sexual desire, arousal, and satisfying sexual events compared to placebo – leading to FDA approval as Vyleesi.

Who Uses PT-141?

PT-141 is used by men experiencing desire-related erectile dysfunction (where the physical mechanism works but desire/arousal is lacking), women with hypoactive sexual desire, couples looking to enhance intimacy, individuals on medications (SSRIs, antidepressants) that suppress libido as a side effect, and anyone experiencing age-related decline in sexual interest.

Clinical References
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women (RECONNECT)
Kingsberg SA, Clayton AH, Pfaus JG, et al.

Obstet Gynecol, 2019. PubMed →

Melanocortin Receptor Agonists and Erectile Function
Molinoff PB, Shadiack AM, Earle D, et al.

Ann N Y Acad Sci, 2003. PubMed →

Bremelanotide: New Drug for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, et al.

Ther Adv Reprod Health, 2019. PubMed →

Clinical References

  1. Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed 12851303
  2. Shadiack AM, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-1144. PubMed 17584134
  3. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PubMed 31429064
  4. Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289. PubMed 33455598
  5. Uckert S, Bannowsky A, Albrecht K, et al. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opin Investig Drugs. 2014;23(11):1477-1483. PubMed 25096243
  6. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PubMed 14963471
  7. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed 31599840
  8. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PubMed 31599847
  9. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. PubMed 27181790
  10. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. PubMed 14999221
Product specifications
Dosage
1mg – 2mg as needed
Cycle
As needed (not daily)
Form
10mg lyophilised powder
Purity
≥98%
Molecular formula
C₅₀H₆₈N₁₄O₁₀
Storage
2–8°C refrigerated
Certificate of Analysis
View COA
Dosing guide

Category-Specific Dosing Guides

Unlike many other sexual health peptides, PT-141 is typically used on an as-needed basis rather than as part of a daily protocol. Published studies and clinical use have generally evaluated intermittent administration with adequate spacing between doses.

  1. 1

    Reconstitute

    Add 2 ml of BAC water to the 10 mg vial to achieve a concentration of 5 mg/ml. At this concentration, 4 units on a U-100 insulin syringe corresponds to approximately 200 mcg, while 20 units corresponds to 1 mg. One vial typically provides 5-10 administrations, depending on the amount used per protocol.

  2. 2

    Dosing

    Clinical studies and commonly reported protocols have evaluated doses ranging from 1-2 mg administered subcutaneously approximately 45-60 minutes before anticipated activity. Many protocols begin at 1 mg before considering higher amounts. Published guidance generally recommends not exceeding 2 mg within a 24-hour period.

  3. 3

    Frequency

    This protocol is typically investigated as an intermittent protocol rather than a daily one. Common usage schedules involve no more than 2–3 administrations per week, with at least 24 hours between doses. Published reports describe activity lasting approximately 6–12 hours, with some observations extending beyond this range.

Side Effect Note

Nausea is among the most frequently reported adverse effects of Bremelanotide and was reported in approximately 40% of participants in clinical studies. Facial flushing has also been reported. As with any peptide protocol, the incidence and severity of side effects may vary between individuals and dosing regimens.

Shipping and returns

Free shipping on orders over £220.

Nearly twice the gain in sexual function as placebo

In a 12-week trial of 327 women, sexual function scores rose 3.6 points on PT-141, against 1.9 on placebo.

Distress - 327 women

Distress about sex dropped 11.1 points

Placebo-6.8
PT-141-11.1

Women in the same 12-week trial also scored how much distress they felt about sex. It fell 11.1 points on PT-141 and 6.8 points on placebo. Satisfying sexual events rose by 0.7 a month, against 0.2.

Clayton et al., Women's Health, 2016
Desire
1,267 women - two phase 3 trials

More desire in two phase 3 trials

In the RECONNECT trials, women with low sexual desire used PT-141 as needed for 24 weeks. They reported more desire and less distress about low desire than women on placebo, in both trials.

Kingsberg et al., Obstetrics & Gynecology, 2019
Long term
684 women - 52-week extension

Gains held for a full year

684 women carried on with PT-141 for another 52 weeks. Those who used it from the start kept their gains in desire and distress scores. No new safety signals appeared.

Simon et al., Obstetrics & Gynecology, 2019
Men
Men with erectile dysfunction - human trial

Worked in men who did not respond well to Viagra

Men who got an erection good enough for sex half the time or less on 100 mg Viagra were given PT-141 injections. Both 4 mg and 6 mg doses gave a significant erectile response against placebo.

Rosen et al., International Journal of Impotence Research, 2004

Sources: Clayton AH et al., Women's Health (London) 2016;12(3):325-37; Kingsberg SA et al., Obstetrics & Gynecology 2019;134(5):899-908; Simon JA et al., Obstetrics & Gynecology 2019;134(5):909-917; Rosen RC et al., International Journal of Impotence Research 2004;16(2):135-42

Rated 4.7 by verified buyers

Customer rating 4.7 Based on 10 reviews Write a review
2026-03-30

This actually makes you want it, not just physically react. Felt the difference within a couple of hours. Much more natural than other options.

Lucien P. Verified Purchase
2026-03-15

One of the few options that works for women. The neurological approach is different and it shows. Very satisfied with results.

Carmen L. Verified Purchase

Leave a Review

Share your experience. Your email won't be published.

0 / 300
Photos (optional)

    Optional · up to 5 photos · JPG, PNG or WebP · max 5 MB each

    How to use PT-141

    Ready in 4 steps, BAC water included. A complete visual guide to preparing, reconstituting, injecting, and storing your peptides safely. Follow each step in order.

    Step 1: Supplies laid out
    1. Supplies laid out Gather your supplies: peptide vial, bacteriostatic water, syringes, alcohol swabs, cotton ball, and bandage.
    Step 2: Remove / flip caps
    2. Remove / flip caps Remove the plastic caps from both vials to expose the rubber stoppers.
    Step 3: Swab the vial stopper
    3. Swab the vial stopper Wipe the top of each vial with an alcohol swab. Let air-dry.
    Step 4: Draw BAC water
    4. Draw BAC water Draw the required amount of bacteriostatic water into the syringe. Use our calculator if unsure.
    Step 5: Inject water into vial
    5. Inject water into vial Inject the water slowly into the peptide vial, letting it run down the inside wall. Do not spray directly onto the powder.
    Step 6: Swirl to dissolve
    6. Swirl to dissolve Gently swirl the vial until the powder dissolves. Do not shake.
    Step 7: Check the solution
    7. Check the solution Check the solution: no undissolved particles, no bubbles, clear liquid. If not, wait and swirl again.
    Step 8: Draw your dose
    8. Draw your dose Draw your dose slowly from the reconstituted peptide vial.
    Step 9: Remove air bubbles
    9. Remove air bubbles Hold the syringe needle-up, flick to move air bubbles to the top, and push the plunger until a small drop appears.
    Step 10: Choose injection site
    10. Choose injection site Choose your injection site: belly fat around the navel or outer thigh. Rotate sites between injections.
    Step 11: Clean the site
    11. Clean the site Clean the injection site with an alcohol swab.
    Step 12: Pinch skin
    12. Pinch skin Pinch a fold of skin at the injection site to lift the subcutaneous fatty tissue away from the muscle.
    Step 13: Insert at 45°
    13. Insert at 45° Insert the needle at a 45° angle into the subcutaneous fatty tissue, usually approximately half the needle length. Do not inject into muscle. Inject slowly.
    Step 14: Cotton-ball press
    14. Cotton-ball press Withdraw the needle and press a cotton ball gently on the site for a few seconds.
    Step 15: Apply bandage
    15. Apply bandage Apply a small bandage.
    Step 16: Sharps disposal
    16. Sharps disposal Dispose of the needle in a sharps container.
    Step 17: Storage
    17. Storage Store reconstituted peptides in the fridge (2-8 °C). Avoid freezing and direct sunlight. Use within 90 days.

    Pre-filled for this product. Adjust values to match your protocol.

    Concentration —
    Volume Per Dose —
    Insulin Syringe Units —
    Total Doses Per Vial —
    Open full calculator

    Frequently Asked Questions

    Common questions answered